Specialty pharmacy Biologics by McKesson reported on Wednesday that it has been selected by Daiichi Sankyo Inc as the exclusive specialty pharmacy provider for TURALIO (pexidartinib) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) with severe morbidity or functional limitations and not amenable to improvement with surgery.
TURALIO, a first-in-class oral tyrosine kinase inhibitor for TGCT, was approved by the US Food and Drug Administration (FDA) on 2 August 2019.
In February 2019, the US FDA accepted, with Priority Review, a New Drug Application (NDA) for TURALIO based on results of Biologics by McKesson's phase 3 ENLIVEN study, the first placebo-controlled study of a systemic investigational therapy in patients with TGCT.
Surgery is the primary mode of treatment for TGCT associated with severe morbidity or functional limitations; however, some patients have disease that is not amenable to resection. Treatment options are limited for these patients because there are no approved systemic therapies for the disease.
Oncternal Presents Clinical Data Update on Cirmtuzumab in Combination with Ibrutinib
US FDA grants approval to Meitheal Pharmaceuticals' Enoxaparin Sodium Injection
FerGene reveals positive results from Phase three nadofaragene firadenovec clinical trial
Amgen receives FDA approval for AVSOLA (infliximab-axxq) across inflammation portfolio
Gelesis raises USD84m in new capital to support commercialisation of Plenity
Veracyte Acquires Exclusive License to NanoString Diagnostics Platform
US FDA Approves Amneal ANDA for Generic Carafate
Advaxis Submits IND Application to US FDA for ADXS-HOT Drug Candidate for Prostate Cancer
Dr Reddy's Laboratories reports availability of Deferasirox Tablets for oral suspension in US market
US FDA grants breakthrough therapy status to Bristol-Myers Squibb's Orencia